Dyne Therapeutics 1 article

The RNA platform of Dyne Therapeutics centers on FORCE antibody oligonucleotide conjugates; as an RNA-therapeutics biotechnology company, it also uses transferrin receptor 1 muscle targeting to shape delivery, specificity or RNA processing. The platform also incorporates oligonucleotide delivery to skeletal muscle and myotonic dystrophy type 1 therapeutics, with toxic RNA knockdown in muscle defining an important chemistry, delivery or RNA-processing feature of the therapeutic approach. For entity matching, the RNA modality is not interchangeable with the company; Dyne Therapeutics is also associated with splice-modifying oligonucleotide therapy.